Aldevron, a Danaher company and global leader in the production of DNA, RNA, and proteins for genomic medicine, and Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodal biosafety testing provider, announced the renewal of their lentiviral plasmid licensing agreement designed to expand access to scalable plasmid solutions for advanced therapy developers.
The renewed collaboration strengthens access to a proprietary off-the-shelf lentiviral plasmid system used in gene-modified cell therapy applications, including CAR-T, TCR-T, and other emerging therapeutic modalities. The agreement combines Aldevron’s cGMP manufacturing expertise with Oxgene’s advanced plasmid engineering and viral vector design capabilities. Oxgene serves as Minaris’ innovation engine and center of excellence for advanced technologies.
Under the expanded agreement, Aldevron will continue manufacturing and supplying the plasmid system across multiple quality grades, including research-use, GMP Source™, and full cGMP production. The companies say the approach is intended to help developers simplify supply chains, reduce manufacturing risk, and accelerate development timelines from discovery through clinical application.
The partnership also provides developers with access to the Oxgene Development Centre in London, where teams can optimize plasmids and genes of interest to improve viral vector productivity and manufacturing performance.
“Our collaboration with Minaris brings together complementary strengths—world-class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline,” said Venkata Indurthi, Chief Science Officer for Aldevron. “By delivering phase-appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability.”
Minaris leadership emphasized the growing need for scalable, high-performing plasmid systems as the global cell and gene therapy sector continues to evolve.
“Through our Oxgene Center of Excellence in London, we bring deep expertise in plasmid design and engineering that is grounded in real-world vector development and manufacturing experience,” said Eytan Abraham, PhD, Chief Technology and Commercial Officer at Minaris. “By combining that design expertise with Aldevron’s manufacturing strength, we help ensure developers have reliable, high-quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success.”
The renewed agreement reflects increasing demand across the advanced therapies sector for integrated manufacturing ecosystems capable of supporting faster development, regulatory readiness, and scalable commercialization pathways.
About Aldevron
Founded in 1998, Aldevron is a Danaher company and global leader focused on enabling the development of next-generation genomic medicines. The company provides DNA, RNA, and protein manufacturing solutions that support scientists and innovators advancing transformative therapies across gene editing, gene therapy, and other emerging modalities.
Aldevron has contributed to several landmark achievements in genomic medicine, including supporting manufacturing efforts tied to the world’s first mRNA-based personalized CRISPR therapy. With facilities located in Fargo, North Dakota; Madison, Wisconsin; and Waltham, Massachusetts, the company continues to expand its role in accelerating scientific discovery and helping bring advanced therapies closer to patients worldwide.
About Minaris
Minaris is a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodal biosafety testing provider. With more than 25 years of CGT manufacturing expertise and over 40 years in biosafety testing, the organization supports innovators from IND through commercial supply.
Through its divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the company provides services including GMP analytics, viral clearance, biosafety testing, and product characterization across both CGT and biologics programs. Minaris operates five global sites across three continents and continues to position itself as a partner helping accelerate advanced therapy development and commercialization worldwide.
About Danaher
Danaher is a global life sciences and diagnostics innovator focused on accelerating scientific and technological advancements that improve human health. Through its ecosystem of operating companies, Danaher works alongside customers to help solve complex scientific and clinical challenges across research, diagnostics, and therapeutic development.
Powered by the Danaher Business System, the company emphasizes operational excellence, innovation, and scalable solutions designed to reduce the time, cost, and risk associated with developing and delivering life-changing therapies. Danaher employs approximately 60,000 associates globally and continues investing in technologies that support a healthier and more sustainable future.
